This document discusses guidelines for the management of postpartum hypertension. It begins by defining various types of hypertension seen during pregnancy including gestational hypertension, preeclampsia, and postpartum hypertension. It then discusses the postpartum course of these conditions and risk factors for postpartum hypertension. The document provides guidance on diagnosing and managing both chronic and new-onset postpartum hypertension, including treatment options and follow-up care after discharge.
This practice bulletin from the American College of Obstetricians and Gynecologists provides guidelines for the clinical management of chronic hypertension in pregnancy. It defines chronic hypertension as hypertension diagnosed or present before pregnancy or before 20 weeks of gestation. The bulletin reviews criteria for diagnosing chronic hypertension, types of chronic hypertension, effects on pregnancy, and management options. It also discusses challenges in differentiating chronic hypertension from gestational hypertension and superimposed preeclampsia. The purpose is to provide an evidence-based approach to chronic hypertension in pregnancy.
This document provides an overview of thyroid function and disorders during pregnancy. It discusses how the thyroid gland and thyroid function tests change normally during pregnancy. It also covers hyperthyroidism and hypothyroidism in pregnancy, including their effects on the fetus and neonate. Key points include that both hyperthyroidism and hypothyroidism can lead to adverse pregnancy outcomes if not properly treated, and maternal thyroid antibodies can affect the fetal thyroid gland. Precise diagnosis and treatment of thyroid disorders is important for maternal and fetal health.
The document summarizes physiological changes in thyroid function during pregnancy and management of hyperthyroidism. Key points:
1) Thyroid binding globulin, TT4, and TT3 levels increase during pregnancy to compensate for decreased FT4 and FT3. TSH decreases in the first trimester and increases in the second and third trimesters.
2) Hyperthyroidism in pregnancy is usually caused by Graves' disease and can cause complications if unmanaged. Treatment involves antithyroid medications like PTU and carbimazole.
3) Treatment aims to control hyperthyroidism rapidly and maintain euthyroidism with the lowest effective drug dose to avoid fetal hypothyroidism or goiter
This document discusses thyroid disease in pregnancy. It begins by outlining the anatomy and physiology of the thyroid gland and how thyroid function changes during pregnancy. It then discusses specific thyroid disorders that can occur during pregnancy, including hyperthyroidism (overactive thyroid), hypothyroidism (underactive thyroid), and subclinical hypothyroidism. For each condition, it describes the potential maternal and fetal effects, diagnostic criteria, and treatment recommendations. The document provides detailed information on evaluating and managing thyroid disease to optimize outcomes for both the mother and baby.
This document discusses several autoimmune and endocrine conditions that can affect pregnancy, including their presentation, diagnosis, and management. It covers thyroid disease, rheumatoid arthritis, immune thrombocytopenic purpura, myasthenia gravis, and systemic lupus erythematosus. For each condition, it describes associated risks for the mother and fetus, as well as recommendations for treatment and monitoring during pregnancy and delivery. The goal is to maintain maternal and fetal health while minimizing medication exposure for the baby.
Maternal thyroid physiology is modulated during pregnancy by increases in hCG, urinary iodide excretion, and thyroxine-binding globulin. Thyroid disorders complicating pregnancy include hyperthyroidism, hypothyroidism, and postpartum thyroiditis. Hyperthyroidism is treated during pregnancy with antithyroid medications to maintain normal thyroid hormone levels. Hypothyroidism requires increasing levothyroxine doses during pregnancy. Postpartum thyroiditis involves transient hyperthyroid and hypothyroid phases due to thyroid autoimmunity after delivery.
1. Thyroid function changes during pregnancy due to increases in thyroid binding globulin, human chorionic gonadotropin, and other factors. This can cause hyperthyroidism or hypothyroidism.
2. Hyperthyroidism occurs in 0.2% of pregnancies, often due to Graves' disease. It increases risk of complications. Hypothyroidism occurs in 2-3% and also increases risks if not treated.
3. Postpartum thyroiditis involves transient hyperthyroidism and/or hypothyroidism after delivery. Long term hypothyroidism can occur. Thyroid cancer diagnosis and treatment requires consideration of pregnancy.
(마더세이프라운드) Thyroid disease in pregnancy mothersafe
This document summarizes the evidence and guidelines regarding screening for thyroid disease during pregnancy. It finds that while screening for subclinical hypothyroidism remains controversial, screening for overt thyroid disease is recommended due to the clear adverse maternal and fetal effects of untreated overt hypothyroidism and hyperthyroidism. Universal screening is superior to selective screening in detecting thyroid dysfunction in pregnant women. Given the high prevalence of thyroid abnormalities in pregnant women, especially in Korea where most women are over 30 years old at their first prenatal visit, universal screening is considered appropriate.
This practice bulletin from the American College of Obstetricians and Gynecologists provides guidelines for the clinical management of chronic hypertension in pregnancy. It defines chronic hypertension as hypertension diagnosed or present before pregnancy or before 20 weeks of gestation. The bulletin reviews criteria for diagnosing chronic hypertension, types of chronic hypertension, effects on pregnancy, and management options. It also discusses challenges in differentiating chronic hypertension from gestational hypertension and superimposed preeclampsia. The purpose is to provide an evidence-based approach to chronic hypertension in pregnancy.
This document provides an overview of thyroid function and disorders during pregnancy. It discusses how the thyroid gland and thyroid function tests change normally during pregnancy. It also covers hyperthyroidism and hypothyroidism in pregnancy, including their effects on the fetus and neonate. Key points include that both hyperthyroidism and hypothyroidism can lead to adverse pregnancy outcomes if not properly treated, and maternal thyroid antibodies can affect the fetal thyroid gland. Precise diagnosis and treatment of thyroid disorders is important for maternal and fetal health.
The document summarizes physiological changes in thyroid function during pregnancy and management of hyperthyroidism. Key points:
1) Thyroid binding globulin, TT4, and TT3 levels increase during pregnancy to compensate for decreased FT4 and FT3. TSH decreases in the first trimester and increases in the second and third trimesters.
2) Hyperthyroidism in pregnancy is usually caused by Graves' disease and can cause complications if unmanaged. Treatment involves antithyroid medications like PTU and carbimazole.
3) Treatment aims to control hyperthyroidism rapidly and maintain euthyroidism with the lowest effective drug dose to avoid fetal hypothyroidism or goiter
This document discusses thyroid disease in pregnancy. It begins by outlining the anatomy and physiology of the thyroid gland and how thyroid function changes during pregnancy. It then discusses specific thyroid disorders that can occur during pregnancy, including hyperthyroidism (overactive thyroid), hypothyroidism (underactive thyroid), and subclinical hypothyroidism. For each condition, it describes the potential maternal and fetal effects, diagnostic criteria, and treatment recommendations. The document provides detailed information on evaluating and managing thyroid disease to optimize outcomes for both the mother and baby.
This document discusses several autoimmune and endocrine conditions that can affect pregnancy, including their presentation, diagnosis, and management. It covers thyroid disease, rheumatoid arthritis, immune thrombocytopenic purpura, myasthenia gravis, and systemic lupus erythematosus. For each condition, it describes associated risks for the mother and fetus, as well as recommendations for treatment and monitoring during pregnancy and delivery. The goal is to maintain maternal and fetal health while minimizing medication exposure for the baby.
Maternal thyroid physiology is modulated during pregnancy by increases in hCG, urinary iodide excretion, and thyroxine-binding globulin. Thyroid disorders complicating pregnancy include hyperthyroidism, hypothyroidism, and postpartum thyroiditis. Hyperthyroidism is treated during pregnancy with antithyroid medications to maintain normal thyroid hormone levels. Hypothyroidism requires increasing levothyroxine doses during pregnancy. Postpartum thyroiditis involves transient hyperthyroid and hypothyroid phases due to thyroid autoimmunity after delivery.
1. Thyroid function changes during pregnancy due to increases in thyroid binding globulin, human chorionic gonadotropin, and other factors. This can cause hyperthyroidism or hypothyroidism.
2. Hyperthyroidism occurs in 0.2% of pregnancies, often due to Graves' disease. It increases risk of complications. Hypothyroidism occurs in 2-3% and also increases risks if not treated.
3. Postpartum thyroiditis involves transient hyperthyroidism and/or hypothyroidism after delivery. Long term hypothyroidism can occur. Thyroid cancer diagnosis and treatment requires consideration of pregnancy.
(마더세이프라운드) Thyroid disease in pregnancy mothersafe
This document summarizes the evidence and guidelines regarding screening for thyroid disease during pregnancy. It finds that while screening for subclinical hypothyroidism remains controversial, screening for overt thyroid disease is recommended due to the clear adverse maternal and fetal effects of untreated overt hypothyroidism and hyperthyroidism. Universal screening is superior to selective screening in detecting thyroid dysfunction in pregnant women. Given the high prevalence of thyroid abnormalities in pregnant women, especially in Korea where most women are over 30 years old at their first prenatal visit, universal screening is considered appropriate.
This document discusses thyroid disorders in pregnancy. It notes that hypothyroidism affects 0.05% of pregnant women while hyperthyroidism, mainly Graves' disease, affects 0.05-0.2%. Postpartum thyroiditis occurs in 5-10% of women. The thyroid gland normally enlarges in pregnancy due to increased vascularity. HCG and estrogen levels rise, decreasing TSH and free T4 levels. Treatment aims to maintain euthyroidism. Hyperthyroidism is treated mainly with antithyroid drugs like PTU or carbimazole. Hypothyroidism is treated with levothyroxine. Postpartum thyroiditis can cause transient hyperthyroidism or hyp
The document discusses thyroid physiology and function during pregnancy. It notes that the hypothalamus-pituitary-thyroid axis is regulated by negative feedback, with TRH and TSH levels inversely related to T3 and T4 levels. During pregnancy, thyroid function is impacted due to increases in TBG, TT4, and TT3 to support fetal development. The document outlines screening recommendations for hypothyroidism in pregnancy, treatment with levothyroxine to maintain normal TSH levels, and potential complications of untreated maternal hypothyroidism such as preterm birth, low birth weight, and impaired neurodevelopment.
Thyroid hormones play an important role in female reproduction and pregnancy. Thyroid dysfunction can affect 2-3% of pregnant women and can lead to adverse outcomes for both mother and fetus if not properly managed. Hypothyroidism is more common than hyperthyroidism in pregnancy. Subclinical hypothyroidism may be associated with risks and its treatment controversial. Overt hypothyroidism should be treated to maintain normal thyroid levels. Graves' disease can worsen or improve during pregnancy depending on the individual, and anti-thyroid medications are used for treatment while avoiding radioiodine. Postpartum thyroiditis can cause temporary thyroid problems after delivery. Careful monitoring and treatment when needed of thyroid conditions is important
1. Thyroid disorders are common in pregnancy, affecting 1-2% of pregnant women. Optimal management is important for pregnancy outcomes.
2. Hypothyroidism and hyperthyroidism can cause complications for both mother and fetus if not treated properly. Levothyroxine is the treatment of choice for hypothyroidism. Antithyroid drugs are used to treat hyperthyroidism.
3. Factors like hCG and estrogen increase thyroid function in pregnancy, requiring adjustments to diagnosis and treatment of thyroid disorders compared to non-pregnant individuals. Monitoring of thyroid levels is important during and after pregnancy.
The document discusses thyroid disease in pregnancy. It describes the physiological changes in thyroid function during pregnancy, including increases in thyroid binding globulin and thyroid hormone levels. It covers the signs, symptoms, risks and treatment of both hyperthyroidism and hypothyroidism in pregnancy. For hyperthyroidism, the most common cause is Graves' disease. Risks include early pregnancy loss, fetal growth issues, and neonatal hyperthyroidism. Treatment involves antithyroid medications. For hypothyroidism, the most common causes are Hashimoto's thyroiditis and iodine deficiency. Risks include infertility, miscarriage, and impaired neurodevelopment. Treatment is levothyroxine supplementation.
Hypothyroidism in pregnancy by DR ALKA MUKHERJEE DR APURVA MUKHERJEE NAGPUR M.S.alka mukherjee
Pregnancy is a period that places great physiological stress on both the mother and the fetus. When pregnancy is compounded by endocrine disorders such as hypothyroidism, the potential for maternal and fetal adverse outcomes can be immense. While a lot of attention has been focused on the adverse fetal outcomes consequent to hypothyroidism, attention is also being gradually directed towards the adverse maternal outcomes of this disorder. Role of antibody positivity in influencing outcomes in a euthyroid woman, also needs further clarification. Prompt diagnosis and treatment of hypothyroidism in pregnancy is very essential. Subclinical hypothyroidism also needs to be detected and treated to prevent adverse outcomes, especially maternal. Since women with hypothyroidism during pregnancy, especially of the autoimmune variety might have a flare up of the disorder post-partum, or might continue to require thyroxine replacement post-partum, adequate follow-up is mandatory. While targeted case finding is generally practised, recent evidence seems to indicate that universal screening might be a better option. In conclusion, routine screening, early confirmation of diagnosis and prompt treatment. Allied with regular post-partum follow up, is required to ensure favourable maternal and fetal outcomes.
Thyroid physiology is perceptibly modified during normal pregnancy. These alterations take place throughout gestation, help to prepare the maternal thyroid gland to cope with the metabolic demands of pregnancy, are reversible post-partum and the interpretation of these changes can pose a challenge to the treating physician.
Hypothyroid Disorders in Obs & Gynae – Case based approach – Part -1 Lifecare Centre
Hypothyroid Disorders in Obs & Gynae – Case based approach – Part -1
Moderator - Dr Meenakshi Sharma
& Dr Puja Dewan
Panelist
Dr Dipti Nabh
Dr Richa Singhal
Dr Manju Sharma
Dr Deepa Gupta
Dr Renu Chawla
Dr Anita Agarwal
This document discusses thyroid function and hypothyroidism during pregnancy. It begins with an overview of thyroid physiology and the changes that occur during pregnancy, including increases in thyroid binding globulin and decreases in free thyroid hormones. It then discusses fetal thyroid development and the risks of maternal hypothyroidism. The document outlines the causes, signs, and laboratory tests for hypothyroidism and how the condition can impact pregnancy outcomes if uncontrolled. It recommends treatment with levothyroxine to maintain thyroid stimulating hormone levels in the appropriate range for pregnancy trimesters. The goal of treatment is to minimize risks of adverse effects for both the mother and fetus.
This document discusses the contemporary management of subclinical hypothyroidism during pre-conception and pregnancy. It begins by outlining the physiological changes in thyroid function that occur during pregnancy, including increases in thyroid-binding globulin and human chorionic gonadotropin that impact thyroid hormone levels. It then defines hypothyroidism and subclinical hypothyroidism. While the risks of untreated overt hypothyroidism on maternal and fetal health are well-established, the risks and benefits of treating subclinical hypothyroidism are still debated. Treatment of subclinical hypothyroidism in pregnancy aims to normalize maternal thyroid function and reduce risks, though randomized controlled trials are still needed.
This document discusses thyrotoxicosis (hyperthyroidism) during pregnancy. It notes the physiological changes in thyroid function during pregnancy, including increases in thyroid binding globulin and decreases in plasma iodide levels. It describes the signs and symptoms of maternal hyperthyroidism as well as its most common cause, Graves' disease. Guidelines are provided for clinical management, including use of thionamide medications like propylthiouracil to control thyroid levels while monitoring the fetus. Treatment may also include beta blockers, iodine, or subtotal thyroidectomy in rare cases. Radioactive iodine therapy is contraindicated in pregnancy due to risks to the fetal thyroid.
This document summarizes thyroid disease in pregnancy. It discusses how thyroid function changes normally during pregnancy, with relative iodine deficiency and increased levels of thyroid binding globulin and T4 in early gestation. It notes that hyperthyroidism in pregnancy is usually caused by Graves' disease. Left untreated, it can lead to risks for both mother and fetus, including heart failure, thyroid storm, growth restriction and preterm labor. Management involves achieving an euthyroid state through medications like thionamides or propranolol, with close monitoring of thyroid function tests during pregnancy and treatment of any thyroid storm that may occur during labor and delivery.
Over the past several years it has been proved that maternal thyroid disorder influence the outcome of mother and fetus, during and also after pregnancy. The most frequent thyroid disorder in pregnancy is maternal hypothyroidism. It is associated with fetal loss, placental abruptions, pre-eclampsia, preterm delivery and reduced intellectual function in the offspring.1 In pregnancy, overt hypothyroidism is seen in 0.2% cases2 and sub clinical hypothyroidism in 2.3% cases3. Fetal loss, fetal growth restriction, pre-eclampsia and preterm delivery are the usual complications of overt hyperthyroidism (low TSH and high T3, T4) seen in 2 of 1000 pregnancies whereas mild or sub clinical hyperthyroidism (suppressed TSH alone) is seen in
1.7% of pregnancies and not associated with adverse outcomes4. Autoimmune positive euthyroid pregnancy shows doubling of incidence of miscarriage and preterm delivery. Worldwide more than 20 million people develop neurological sequel due to intra uterine, iodine deprivation5. Other problems of thyroid disorders in pregnancy are post partum thyroiditis, thyroid nodules and cancer, hyper emesis gravidarum etc. Debates and disputes persist regarding several protocol and management plan in this specific spectrum of diseases.
Subclinical hypothyroidism in patients with recurrent early miscarriage (1)Mohamed Ashour
This study aimed to assess the prevalence of subclinical hypothyroidism in Egyptian women with recurrent early miscarriage. The study included 150 women with recurrent early miscarriage and 150 controls. The results found no significant differences in TSH, FT3 or FT4 levels between the two groups. Subclinical hypothyroidism was found in 8% of women with recurrent miscarriage and 4.7% of controls, with no significant association between subclinical hypothyroidism and recurrent early pregnancy loss. The study recommends further research on the effects of subclinical hypothyroidism on pregnancy outcomes.
This document discusses thyroid disorders in pregnancy. It notes that thyroid disorders are common in pregnancy, affecting 1-2% of pregnancies with overt disease and 3-5% with subclinical disease. Thyroid screening and treatment in pregnancy can help improve outcomes for both mother and baby, though guidelines vary on who and when to screen. The document reviews thyroid changes in pregnancy, screening recommendations, treatment of hypothyroidism and hyperthyroidism, and complications like postpartum thyroid dysfunction.
hyperthyroidism, thyrotoxicosis, grave disease, thyroid storm, pregnancy, high risk pregnancy, pregnancy complications, management of thyrotoxicosis and thyroid storm in pregnancy
ABSTRACT- Thyroid disease commonly affects women of childbearing age and is the second most common
endocrinological disorder diagnosed in pregnancy after gestational diabetes. In normal gestation, the thyroid
gland adapts its structure and function to satisfy increasing functional demand. The marked physiological
changes that occur during normal pregnancy make it necessary to use specific reference ranges in interpretation
of thyroid function test. It is well documented that thyroid disorders are associated with maternal and fetal
complications during gestation, and its deleterious effects can also extend beyond pregnancy and delivery.
Available epidemiological data report widely varying prevalence rates of thyroid disorders during the antenatal
period. However, the need for universal thyroid screening remains controversial. Subclinical thyroid
dysfunction is very frequent but easily missed without specific screening programs. Furthermore, an appropriate
management is crucial to prevent adverse maternal and fetal outcomes. Despite the correlation between thyroid
function during pregnancy and maternal and fetal outcomes is a widely discussed issue, it remains important to
clarify several points regarding screening, diagnosis, and treatment of thyroid dysfunction in pregnant ladies. In
this article we try to discuss the physiological changes of the thyroid gland to meet the challenges of increased
metabolic demands during pregnancy and focusing on pathological function changes; we also try to summarize
the best way of screening, diagnosis and treatment of thyroid dysfunction during pregnancy to improve maternal
and fetal outcomes.
Key Words: Pregnancy, Thyroid gland, Hypothyroidism, Hyperthyroidism, Thyroid stimulating hormone
THYROID SCREENING IN PREGNANCY – IS IT WARRANTED?, Dr. Jyoti Bhaskar Lifecare Centre
This document discusses thyroid screening in pregnancy. It notes that hypothyroidism is a common endocrine disorder in pregnancy, affecting 0.3-0.5% of women with overt hypothyroidism and 2-7% with subclinical hypothyroidism. Maternal hypothyroidism increases risks for infertility, miscarriage, preterm birth, low birth weight, and impaired fetal neurodevelopment. While guidelines vary, most recommend screening high-risk groups like those with thyroid symptoms, history of thyroid problems, infertility, or planning pregnancy. Screening all pregnant women once, typically in the first trimester, can help identify disorders and minimize complications through treatment.
Hypertensive disorders in pregnancy by Heba Heba Omoush
This document discusses hypertensive disorders of pregnancy, including preeclampsia and eclampsia. It defines the conditions and classifications, describes risk factors and potential complications, and outlines diagnostic criteria and management approaches. Preeclampsia is a leading cause of maternal mortality characterized by new hypertension and proteinuria after 20 weeks of gestation. It can range from mild to severe depending on symptoms, and severe preeclampsia is treated with aggressive delivery and antihypertensive medications. Eclampsia involves seizures in preeclampsia patients and is managed with magnesium sulfate. Overall, delivery is the only cure for preeclampsia and management aims to carefully control blood pressure and monitor for maternal-fetal complications.
Cardiovascular diseases of pregnancy.pptgreatdiablo
This document discusses cardiovascular and respiratory disorders in pregnancy. It provides classifications and definitions for hypertensive disorders in pregnancy including gestational hypertension, preeclampsia, eclampsia, chronic hypertension, and HELLP syndrome. It discusses the pathophysiology, evaluation, management, and treatment of these conditions. It also discusses respiratory disorders like asthma and influenza that can occur during pregnancy.
This document discusses thyroid disorders in pregnancy. It notes that hypothyroidism affects 0.05% of pregnant women while hyperthyroidism, mainly Graves' disease, affects 0.05-0.2%. Postpartum thyroiditis occurs in 5-10% of women. The thyroid gland normally enlarges in pregnancy due to increased vascularity. HCG and estrogen levels rise, decreasing TSH and free T4 levels. Treatment aims to maintain euthyroidism. Hyperthyroidism is treated mainly with antithyroid drugs like PTU or carbimazole. Hypothyroidism is treated with levothyroxine. Postpartum thyroiditis can cause transient hyperthyroidism or hyp
The document discusses thyroid physiology and function during pregnancy. It notes that the hypothalamus-pituitary-thyroid axis is regulated by negative feedback, with TRH and TSH levels inversely related to T3 and T4 levels. During pregnancy, thyroid function is impacted due to increases in TBG, TT4, and TT3 to support fetal development. The document outlines screening recommendations for hypothyroidism in pregnancy, treatment with levothyroxine to maintain normal TSH levels, and potential complications of untreated maternal hypothyroidism such as preterm birth, low birth weight, and impaired neurodevelopment.
Thyroid hormones play an important role in female reproduction and pregnancy. Thyroid dysfunction can affect 2-3% of pregnant women and can lead to adverse outcomes for both mother and fetus if not properly managed. Hypothyroidism is more common than hyperthyroidism in pregnancy. Subclinical hypothyroidism may be associated with risks and its treatment controversial. Overt hypothyroidism should be treated to maintain normal thyroid levels. Graves' disease can worsen or improve during pregnancy depending on the individual, and anti-thyroid medications are used for treatment while avoiding radioiodine. Postpartum thyroiditis can cause temporary thyroid problems after delivery. Careful monitoring and treatment when needed of thyroid conditions is important
1. Thyroid disorders are common in pregnancy, affecting 1-2% of pregnant women. Optimal management is important for pregnancy outcomes.
2. Hypothyroidism and hyperthyroidism can cause complications for both mother and fetus if not treated properly. Levothyroxine is the treatment of choice for hypothyroidism. Antithyroid drugs are used to treat hyperthyroidism.
3. Factors like hCG and estrogen increase thyroid function in pregnancy, requiring adjustments to diagnosis and treatment of thyroid disorders compared to non-pregnant individuals. Monitoring of thyroid levels is important during and after pregnancy.
The document discusses thyroid disease in pregnancy. It describes the physiological changes in thyroid function during pregnancy, including increases in thyroid binding globulin and thyroid hormone levels. It covers the signs, symptoms, risks and treatment of both hyperthyroidism and hypothyroidism in pregnancy. For hyperthyroidism, the most common cause is Graves' disease. Risks include early pregnancy loss, fetal growth issues, and neonatal hyperthyroidism. Treatment involves antithyroid medications. For hypothyroidism, the most common causes are Hashimoto's thyroiditis and iodine deficiency. Risks include infertility, miscarriage, and impaired neurodevelopment. Treatment is levothyroxine supplementation.
Hypothyroidism in pregnancy by DR ALKA MUKHERJEE DR APURVA MUKHERJEE NAGPUR M.S.alka mukherjee
Pregnancy is a period that places great physiological stress on both the mother and the fetus. When pregnancy is compounded by endocrine disorders such as hypothyroidism, the potential for maternal and fetal adverse outcomes can be immense. While a lot of attention has been focused on the adverse fetal outcomes consequent to hypothyroidism, attention is also being gradually directed towards the adverse maternal outcomes of this disorder. Role of antibody positivity in influencing outcomes in a euthyroid woman, also needs further clarification. Prompt diagnosis and treatment of hypothyroidism in pregnancy is very essential. Subclinical hypothyroidism also needs to be detected and treated to prevent adverse outcomes, especially maternal. Since women with hypothyroidism during pregnancy, especially of the autoimmune variety might have a flare up of the disorder post-partum, or might continue to require thyroxine replacement post-partum, adequate follow-up is mandatory. While targeted case finding is generally practised, recent evidence seems to indicate that universal screening might be a better option. In conclusion, routine screening, early confirmation of diagnosis and prompt treatment. Allied with regular post-partum follow up, is required to ensure favourable maternal and fetal outcomes.
Thyroid physiology is perceptibly modified during normal pregnancy. These alterations take place throughout gestation, help to prepare the maternal thyroid gland to cope with the metabolic demands of pregnancy, are reversible post-partum and the interpretation of these changes can pose a challenge to the treating physician.
Hypothyroid Disorders in Obs & Gynae – Case based approach – Part -1 Lifecare Centre
Hypothyroid Disorders in Obs & Gynae – Case based approach – Part -1
Moderator - Dr Meenakshi Sharma
& Dr Puja Dewan
Panelist
Dr Dipti Nabh
Dr Richa Singhal
Dr Manju Sharma
Dr Deepa Gupta
Dr Renu Chawla
Dr Anita Agarwal
This document discusses thyroid function and hypothyroidism during pregnancy. It begins with an overview of thyroid physiology and the changes that occur during pregnancy, including increases in thyroid binding globulin and decreases in free thyroid hormones. It then discusses fetal thyroid development and the risks of maternal hypothyroidism. The document outlines the causes, signs, and laboratory tests for hypothyroidism and how the condition can impact pregnancy outcomes if uncontrolled. It recommends treatment with levothyroxine to maintain thyroid stimulating hormone levels in the appropriate range for pregnancy trimesters. The goal of treatment is to minimize risks of adverse effects for both the mother and fetus.
This document discusses the contemporary management of subclinical hypothyroidism during pre-conception and pregnancy. It begins by outlining the physiological changes in thyroid function that occur during pregnancy, including increases in thyroid-binding globulin and human chorionic gonadotropin that impact thyroid hormone levels. It then defines hypothyroidism and subclinical hypothyroidism. While the risks of untreated overt hypothyroidism on maternal and fetal health are well-established, the risks and benefits of treating subclinical hypothyroidism are still debated. Treatment of subclinical hypothyroidism in pregnancy aims to normalize maternal thyroid function and reduce risks, though randomized controlled trials are still needed.
This document discusses thyrotoxicosis (hyperthyroidism) during pregnancy. It notes the physiological changes in thyroid function during pregnancy, including increases in thyroid binding globulin and decreases in plasma iodide levels. It describes the signs and symptoms of maternal hyperthyroidism as well as its most common cause, Graves' disease. Guidelines are provided for clinical management, including use of thionamide medications like propylthiouracil to control thyroid levels while monitoring the fetus. Treatment may also include beta blockers, iodine, or subtotal thyroidectomy in rare cases. Radioactive iodine therapy is contraindicated in pregnancy due to risks to the fetal thyroid.
This document summarizes thyroid disease in pregnancy. It discusses how thyroid function changes normally during pregnancy, with relative iodine deficiency and increased levels of thyroid binding globulin and T4 in early gestation. It notes that hyperthyroidism in pregnancy is usually caused by Graves' disease. Left untreated, it can lead to risks for both mother and fetus, including heart failure, thyroid storm, growth restriction and preterm labor. Management involves achieving an euthyroid state through medications like thionamides or propranolol, with close monitoring of thyroid function tests during pregnancy and treatment of any thyroid storm that may occur during labor and delivery.
Over the past several years it has been proved that maternal thyroid disorder influence the outcome of mother and fetus, during and also after pregnancy. The most frequent thyroid disorder in pregnancy is maternal hypothyroidism. It is associated with fetal loss, placental abruptions, pre-eclampsia, preterm delivery and reduced intellectual function in the offspring.1 In pregnancy, overt hypothyroidism is seen in 0.2% cases2 and sub clinical hypothyroidism in 2.3% cases3. Fetal loss, fetal growth restriction, pre-eclampsia and preterm delivery are the usual complications of overt hyperthyroidism (low TSH and high T3, T4) seen in 2 of 1000 pregnancies whereas mild or sub clinical hyperthyroidism (suppressed TSH alone) is seen in
1.7% of pregnancies and not associated with adverse outcomes4. Autoimmune positive euthyroid pregnancy shows doubling of incidence of miscarriage and preterm delivery. Worldwide more than 20 million people develop neurological sequel due to intra uterine, iodine deprivation5. Other problems of thyroid disorders in pregnancy are post partum thyroiditis, thyroid nodules and cancer, hyper emesis gravidarum etc. Debates and disputes persist regarding several protocol and management plan in this specific spectrum of diseases.
Subclinical hypothyroidism in patients with recurrent early miscarriage (1)Mohamed Ashour
This study aimed to assess the prevalence of subclinical hypothyroidism in Egyptian women with recurrent early miscarriage. The study included 150 women with recurrent early miscarriage and 150 controls. The results found no significant differences in TSH, FT3 or FT4 levels between the two groups. Subclinical hypothyroidism was found in 8% of women with recurrent miscarriage and 4.7% of controls, with no significant association between subclinical hypothyroidism and recurrent early pregnancy loss. The study recommends further research on the effects of subclinical hypothyroidism on pregnancy outcomes.
This document discusses thyroid disorders in pregnancy. It notes that thyroid disorders are common in pregnancy, affecting 1-2% of pregnancies with overt disease and 3-5% with subclinical disease. Thyroid screening and treatment in pregnancy can help improve outcomes for both mother and baby, though guidelines vary on who and when to screen. The document reviews thyroid changes in pregnancy, screening recommendations, treatment of hypothyroidism and hyperthyroidism, and complications like postpartum thyroid dysfunction.
hyperthyroidism, thyrotoxicosis, grave disease, thyroid storm, pregnancy, high risk pregnancy, pregnancy complications, management of thyrotoxicosis and thyroid storm in pregnancy
ABSTRACT- Thyroid disease commonly affects women of childbearing age and is the second most common
endocrinological disorder diagnosed in pregnancy after gestational diabetes. In normal gestation, the thyroid
gland adapts its structure and function to satisfy increasing functional demand. The marked physiological
changes that occur during normal pregnancy make it necessary to use specific reference ranges in interpretation
of thyroid function test. It is well documented that thyroid disorders are associated with maternal and fetal
complications during gestation, and its deleterious effects can also extend beyond pregnancy and delivery.
Available epidemiological data report widely varying prevalence rates of thyroid disorders during the antenatal
period. However, the need for universal thyroid screening remains controversial. Subclinical thyroid
dysfunction is very frequent but easily missed without specific screening programs. Furthermore, an appropriate
management is crucial to prevent adverse maternal and fetal outcomes. Despite the correlation between thyroid
function during pregnancy and maternal and fetal outcomes is a widely discussed issue, it remains important to
clarify several points regarding screening, diagnosis, and treatment of thyroid dysfunction in pregnant ladies. In
this article we try to discuss the physiological changes of the thyroid gland to meet the challenges of increased
metabolic demands during pregnancy and focusing on pathological function changes; we also try to summarize
the best way of screening, diagnosis and treatment of thyroid dysfunction during pregnancy to improve maternal
and fetal outcomes.
Key Words: Pregnancy, Thyroid gland, Hypothyroidism, Hyperthyroidism, Thyroid stimulating hormone
THYROID SCREENING IN PREGNANCY – IS IT WARRANTED?, Dr. Jyoti Bhaskar Lifecare Centre
This document discusses thyroid screening in pregnancy. It notes that hypothyroidism is a common endocrine disorder in pregnancy, affecting 0.3-0.5% of women with overt hypothyroidism and 2-7% with subclinical hypothyroidism. Maternal hypothyroidism increases risks for infertility, miscarriage, preterm birth, low birth weight, and impaired fetal neurodevelopment. While guidelines vary, most recommend screening high-risk groups like those with thyroid symptoms, history of thyroid problems, infertility, or planning pregnancy. Screening all pregnant women once, typically in the first trimester, can help identify disorders and minimize complications through treatment.
Hypertensive disorders in pregnancy by Heba Heba Omoush
This document discusses hypertensive disorders of pregnancy, including preeclampsia and eclampsia. It defines the conditions and classifications, describes risk factors and potential complications, and outlines diagnostic criteria and management approaches. Preeclampsia is a leading cause of maternal mortality characterized by new hypertension and proteinuria after 20 weeks of gestation. It can range from mild to severe depending on symptoms, and severe preeclampsia is treated with aggressive delivery and antihypertensive medications. Eclampsia involves seizures in preeclampsia patients and is managed with magnesium sulfate. Overall, delivery is the only cure for preeclampsia and management aims to carefully control blood pressure and monitor for maternal-fetal complications.
Cardiovascular diseases of pregnancy.pptgreatdiablo
This document discusses cardiovascular and respiratory disorders in pregnancy. It provides classifications and definitions for hypertensive disorders in pregnancy including gestational hypertension, preeclampsia, eclampsia, chronic hypertension, and HELLP syndrome. It discusses the pathophysiology, evaluation, management, and treatment of these conditions. It also discusses respiratory disorders like asthma and influenza that can occur during pregnancy.
This document provides guidelines for diagnosing and managing preeclampsia. It defines hypertension in pregnancy and classifies hypertensive disorders. Preeclampsia is diagnosed based on new onset hypertension and proteinuria or other maternal organ dysfunction after 20 weeks of gestation. It outlines risk factors, pathophysiology affecting multiple organ systems, and international diagnostic criteria. Management involves monitoring for severe features, controlling blood pressure and delivering the baby to resolve symptoms. Accurate blood pressure measurement requires standardized technique and interpretation of Korotkoff sounds.
Hypertensive disorders in pregnancy (HDP) are a common cause of maternal and infant health problems and death. HDP include gestational hypertension, preeclampsia, and eclampsia. Risk factors include being young, older than 35, having previous HDP, obesity, diabetes, or kidney disease. Symptoms of severe preeclampsia include headaches, vision issues, low platelets, elevated liver enzymes, pain in the upper right abdomen, HELLP syndrome, or high creatinine. All pregnant people should take calcium and those at higher risk may benefit from low-dose aspirin. HDP requires frequent monitoring, control of blood pressure, delivery by 38 weeks for gestational hypertension or earlier for pre
UPDATES ON HPT DISORDERS OF PREGNANCY by dr yahya.pptxMaryamYahya8
This document provides an overview of hypertensive disorders in pregnancy. It defines the main categories of hypertensive disorders such as chronic hypertension, gestational hypertension, preeclampsia, and preeclampsia superimposed on chronic hypertension. It discusses the pathophysiology, risk factors, diagnosis, and management of these conditions. Hypertensive disorders are a major cause of maternal and fetal morbidity and mortality worldwide. Accurate classification is important for optimizing care and reducing health risks.
Evaluation and management of hypertension in pregnancyImran Hassan
This document discusses the evaluation and management of hypertension in pregnancy. It defines the various hypertensive disorders that can occur during pregnancy, including preeclampsia, chronic hypertension, chronic hypertension with superimposed preeclampsia, and gestational hypertension. It provides details on the signs, symptoms, diagnostic criteria, risk factors, prevention, and treatment approaches for each condition. The management of hypertension during pregnancy aims to prevent complications through careful monitoring, timely delivery when indicated, and antihypertensive treatment as needed.
HYPERTENSION IN PREGNANCY SOGON FINAL ONE.pptAdeniyiAkiseku
Hypertensive disorders are the most common medical complication of pregnancy
It complicates up to 10% of pregnancies
It is a leading cause of maternal and perinatal morbidity and mortality worldwide
Rates are rising because of the older, more obese obstetric population with medical issues
Recent guidline for management of HDP.Prof Salah RoshdySalah Roshdy AHMED
This document provides guidelines for the management of hypertensive disorders of pregnancy according to recent 2019 classifications. It defines hypertension in pregnancy, classifies the hypertensive disorders, and differentiates between preeclampsia, severe preeclampsia, and chronic hypertension. Risk factors for developing preeclampsia are identified. The document provides a practical guide for diagnosing and managing these conditions, including recommendations for accurate blood pressure measurement and proteinuria quantification.
Hypertensive disorders in pregnancy are common, affecting up to 10% of pregnancies, and can cause maternal and fetal morbidity and mortality. There are several classifications of hypertensive disorders including gestational hypertension, pre-eclampsia, chronic hypertension, and pre-eclampsia superimposed on chronic hypertension. Pre-eclampsia is defined by new onset hypertension and proteinuria after 20 weeks of gestation. It is caused by abnormal placentation leading to endothelial dysfunction and clinical manifestations include hypertension, proteinuria, and potential multi-organ involvement. Management involves monitoring, controlling blood pressure, preventing seizures with magnesium sulfate, and often involves early delivery.
Hypertensive disorders during pregnancy pptxShabnam Shaikh
Hypertensive disorders are a major cause of maternal and neonatal morbidity and mortality globally. This document discusses the classification, risk factors, signs and symptoms, diagnosis, and management of hypertensive disorders in pregnancy including gestational hypertension, preeclampsia, chronic hypertension, and eclampsia. It provides guidelines for monitoring, treatment with antihypertensive medications, delivery timing, and postpartum care for women with mild or severe forms of these conditions. The goal of treatment is to prevent maternal complications while allowing for fetal lung maturity as determined by gestational age.
Management of Pre-eclampsiaand eclampsia Case discussionsMouafak Alhadithy
The document discusses the management of pre-eclampsia and eclampsia, defining the conditions and outlining diagnostic criteria and treatment approaches. It provides case studies of patients presenting with hypertension in pregnancy and describes how to evaluate and treat the patients, including through antihypertensive medication, magnesium sulfate administration, and decisions around delivery timing and method. The goal of management is to terminate the pregnancy safely while restoring the health of both the mother and newborn.
This document provides an overview of a presentation on the principles of managing hypertensive disorders of pregnancy. It begins with an introduction on the epidemiology of hypertension in pregnancy. It then covers the classification, risk factors, clinical presentation, management, and complications of hypertensive disorders. For management, it discusses controlling blood pressure, preventing convulsions like eclampsia, and delivering the fetus. It emphasizes the importance of careful monitoring, early detection, and appropriate treatment to optimize maternal and fetal outcomes for these potentially dangerous conditions.
HELLP syndrome is a complication of preeclampsia that involves hemolysis, elevated liver enzymes, and low platelet count. It usually develops before delivery under 37 weeks gestation or within 48 hours postpartum. Risk of life-threatening complications depends on gestational age, obstetric complications, and preexisting conditions. Patients should be hospitalized and treated initially for severe preeclampsia with magnesium sulfate and antihypertensives. Delivery can be delayed up to 48 hours for corticosteroids if mother and fetus are stable. Close monitoring is needed postpartum due to risks of hemorrhage, organ failure, or rupture of liver hematomas.
This document discusses hypertensive disorders of pregnancy including preeclampsia, gestational hypertension, chronic hypertension, and HELLP syndrome. It covers the epidemiology, risk factors, etiology, pathogenesis, diagnosis, investigations, and management of these conditions. Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality worldwide. Careful monitoring and treatment of blood pressure and seizures is important in management.
C.G. is a 39-year-old pregnant woman presenting with increased blood pressure and swelling. At 28 weeks gestation, her blood pressure was 180/100. She was diagnosed with preeclampsia based on her gestational hypertension and proteinuria. Preeclampsia is a hypertensive disorder of pregnancy affecting 7-10% of pregnancies. It is characterized by new onset hypertension and proteinuria after 20 weeks of gestation. Symptoms can range from mild to severe, including headaches, visual disturbances, RUQ pain, and others. Progression of preeclampsia must be closely monitored to determine optimal timing of delivery to prevent maternal and fetal complications.
HYPERTENSIVE DISORDER IN PREGNANCY.pptxHannatAboud
This document discusses hypertensive disorders in pregnancy, including preeclampsia. It defines the different types of hypertension during pregnancy and outlines risk factors and pathophysiology of preeclampsia. The key theories around the abnormal trophoblastic invasion and immunological and vasoconstrictor/vasodilator imbalances are summarized. Diagnosis, management including controlling blood pressure, preventing eclampsia and timely delivery, and potential complications are covered at a high level. Management involves careful monitoring, controlling hypertension and seizures, delivering the baby when indicated based on gestational age and severity of symptoms, and following up postpartum.
This document discusses recent advances in pre-eclampsia, eclampsia, and related disorders. It defines these conditions, outlines their signs and symptoms, risk factors, diagnosis, and management. Some key points include:
- Pre-eclampsia is defined by new onset hypertension and proteinuria after 20 weeks of gestation. It can progress to eclampsia, which is characterized by new onset seizures.
- Risk factors include nulliparity, obesity, family history, and prior pre-eclampsia.
- Management involves monitoring for severity, administering magnesium sulfate to prevent seizures, treating hypertension, and often delivering the baby.
- Related conditions like HELLP syndrome, posterior reversible en
Similar to Dr darweish postpartum hypertensin (20)
PGx Analysis in VarSeq: A User’s PerspectiveGolden Helix
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
3. • DOI: 10.1111/j.1744-4667.2012.00095.x 2012;14:99–105
• The Obstetrician & Gynaecologist (TOG)…http://onlinetog.org...Review
• New-onset hypertension in pregnancy: a review of the long-term maternal
effects
6. • Why …Postnatal Clinical Guidelines ??
• In the current climate of early postnatal discharge both hospital
and community teams need to have referral and management
guidelines in place.
• The 6-week postnatal visit
• It has recently been reported that up to 13% of women initially
thought to have a diagnosis of pre-eclampsia or pregnancy-
induced hypertension will have underlying disease not suspected
antenatally.
RCOG..Tog,.
9. • The puerperium
• The term puerperium refers to the period of about 6-8 weeks
following delivery during which the changes produced by
pregnancy regress.
• Blood pressure changes.
• Postpartum course of:
Gestational hypertension.
Pre-eclampsia.
HELLP Syndrome.
Eclampsia.
11. • Blood pressure in the puerperium
• Following uncomplicated pregnancy most
women will experience increased BP during the
postpartum period such that systolic and
diastolic measurements are increased by an
average of 6 mmHg and 4 mmHg, respectively,
over the first 4 days.
• Furthermore, following uncomplicated pregnancy, up to 12% of
patients will have a recorded diastolic pressure greater than 100
mmHg in the first few days after delivery.
RCOG, TOG
15. • Pre-eclampsia in the puerperium
• Proteinuria:
• Studies of continuing proteinuria following
pregnancy complicated by pre-eclampsia have
varying results
• Proteinuria usually begins to improve within a
few days; however, in women with several
grams of protein excretion, complete resolution
may take weeks to months.
21. • Women at risk of postnatal hypertension:
• The largest group of women with
postpartum hypertension are those who
have developed hypertension in the
antenatal period, however, hypertension
can occur de novo following delivery.
RCOG, TOG,2013
23. • Women at risk of postnatal hypertension: Table 1.
• -
RCOG, TOG,2013
24. • New-onset postpartum hypertension
• Hypertension diagnosed for the first time in women with
normotensive gestations within 2 weeks after delivery. The
incidence of new-onset postpartum hypertension is unknown.
• There is no reliable method of early detection.
• For Diagnosis (early detection) of postpartum hypertension:
>>>>> NICE guidelines
26. • Management of ongoing postnatal hypertension:
• 1-Patients with ‘chronic’ hypertension.
• 2-Women without chronic hypertension
[Hypertension arising during pregnancy or in the
peurperium].
Tog
27. • Management of ongoing postnatal hypertension:
• Women without chronic hypertension
include:
• Gestational hypertension.
• Preeclampsia/Eclampsia.
• New onset postpartrum hypertension [diagnosed
for the first time in the postpartum period].
RCOG..Tog.
28. • Management of ongoing postnatal hypertension.
• 1-Patients with existing (chronic) hypertension:
• In situations where hypertension predates
pregnancy (chronic) switch to the pre-pregnancy
dose of the patient’s usual agent/s.
• Women who were previously using diuretics
should consider an alternative while they are
breastfeeding.
• NB. It is advisable to stop methyldopa following
because of its association with depression.
Tog,.
29. • Management of ongoing postnatal hypertension.
• 2-Women without chronic hypertension
• [=Hypertension arising during pregnancy or in the
peurperium].
• Gestational Hypertension
• Preeclampsia/eclampsia.
• New onset postpartrum hypertension.
Tog,2013.
30. • Management of ongoing postnatal hypertension.
• 2-Women without chronic hypertension
• In patients who were normotensive before
pregnancy, one of the most difficult problems is
deciding which women should have
antihypertensives prescribed following delivery.
Tog
31. • Women without chronic hypertension
• it might be suggested that women who have required
‘antihypertensives’ in the antenatal period, women who
have been delivered before 37 weeks of gestation
because of hypertension and women who have had
severe hypertension are most likely to benefit.
33. • Treatment …
• Women without chronic hypertension: -
• A suggested regimen of starting treatment in the
early postnatal period might be ‘labetalol’
(providing there is no history of asthma) with
second and third-line agents of calcium
antagonist and an ACE inhibitor (such as
enalapril).
Tog
36. • Treatment …
• Women without chronic hypertension: —
• Acute episodes of hypertension in the postnatal
period should be managed in the same manner
as antenatal or intrapartum episodes.
• The agents of choice are:
• Labetalol (oral or intravenous).
• Nifedipine (oral) or
• Hydralazine (IV) : NB. its use as a first-line drug has been
questioned.
Tog
39. • Women without chronic hypertension:
• Follow-up after discharge:
• Once discharged, ‘BP’ should measured on
alternate days for the first 2 weeks.
• Refer for medical review if two measurements
>150/ 100 mmHg are obtained.
• Hospital review will be required if patients report
symptoms of pre-eclampsia or if ‘BP’ is >160/100
mmHg.
RCOG…Tog.
40. • Women without chronic hypertension:
• Follow-up after discharge:
• At 2 weeks: medication should be reduced when
BP is measured at “130–140/80–90” mmHg.
• NB. Most women who commence postnatal
antihypertensives will require treatment for at
least 2 weeks and some women, particularly
women with early onset or severe disease may
need to continue beyond 6 weeks.
RCOG…Tog.
41. • Women without chronic hypertension:
• Follow-up after discharge:
• If medication is required beyond 6 weeks
then further medical review should be
arranged to investigate the possibility of an
underlying cause.
RCOG…Tog.
42. • Women without chronic hypertension:
• Follow-up after discharge:
• The 6-week postnatal visit
• Establish the diagnosis.
• Counselling ….
Recurrence rate
Prophylaxis during a future pregnancy
Advise: lifestyle changes
ACOG.. January..2019.
43. • Women without chronic hypertension:
• Follow-up after discharge:
• The 6-week postnatal visit is an opportunity to
establish the diagnosis and to discuss implications
for future pregnancies.
• All women who have had a diagnosis of pre-
eclampsia should have their BP measured and the
urine tested for proteinuria.
ACOG.. January..2019.
44. • Women without chronic hypertension:
• The 6-week postnatal visit ….COUNSELLING:
• Recurrence rate
[i.e. the risk of pre-eclampsia in a subsequent pregnancy]:
• Severe, early onset pre-eclampsia has a
recurrence rate up to 40% in future pregnancies
(although generally the onset of problems is 2–3 weeks
later and it is less severe than in the first pregnancy).
• Women who present with milder disease, nearer
to term have a risk of recurrence nearer to 10%.
ACOG.. January..2019
45. • Women without chronic hypertension:
• The 6-week postnatal visit ….COUNSELLING:
• Women at increased risk should be
offered low-dose aspirin and increased
BP surveillance during a future
pregnancy.
Tog
ACOG.. January..2019
47. • Clinical Risk Factors and Aspirin Use.
• Risk factors of preeclampsia
• HIGH RISK
• Recommendation: Recommend low-dose aspirin if the
patient has one or more of these high-risk factors.
ACOG, January 2019
48. • Clinical Risk Factors and Aspirin Use.
• Risk factors of preeclampsia
• Moderate RISK
• *Recommendation: Consider low-dose aspirin if the patient has more than
one of these moderate-risk factors.
ACOG, January 2019
49. • Clinical Risk Factors and Aspirin Use
• Clinical Recommendations
• Low-dose (81 mg/day) aspirin for
preeclampsia prophylaxis, should be
initiated between 12 weeks and 28 weeks
of gestation (optimally before 16 weeks of
gestation) and continuing until delivery.
50. • Women without chronic hypertension:
• The 6-week postnatal visit ….COUNSELLING:
• Finally, it is increasingly recognised that pre-
eclampsia is a risk factor for developing
cardiovascular disease in later life and patients
should be made aware of this so that they have
the opportunity make lifestyle choices to
minimise their risk.
• Simple lifestyle changes may help reduce these
risks.
Tog,2013
51. Senior Consultant …Obs/Gyn.
• Egypt..MOH..
• Head of Obs/ Gyn department…Damietta General Hospital.
Dr. Mostafa Darweish
Dr. Mostafa Darweish 51